Navigation Links
US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
Date:6/2/2008

HOUSTON, June 2 /PRNewswire/ -- Physicians affiliated with the US Oncology Research Network are presenting the results of their clinical research at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) held May 30 - June 3, 2008 in Chicago.

Dr. Joyce O'Shaughnessy of Texas Oncology-Baylor Charles A Sammons Cancer Center, an affiliate of US Oncology, gave an oral presentation on findings from a randomized Phase III trial that studied lapatanib (L) alone and in combination with trastuzumab (T) in patients with HER2+ metastatic breast cancer who progressed on trastuzumab. The research is the largest study of two targeted agents in HER2+ metastatic breast cancer and the first to demonstrate the synergy of lapatanib and trastuzumab in a Phase III setting.

The research found that improved clinical outcome was achieved with the combination of L+T in patients progressing on T-based therapy and without substantial change in the side-effect profile. The role of combined anti-HER2 therapy, in combination with chemotherapy, in less heavily pretreated patients with early stage disease is ongoing in the Adjuvant L and/or T Treatment Optimization (ALTTO) study.

"More complete HER2 blockade with lapatinib and trastuzumab benefits patients whose metastatic breast cancer (MBC) is progressing in spite of trastuzumab therapy," said Dr. O'Shaughnessy. "This combination is an important new therapeutic strategy for HER2+ MBC patients, one that does not contain chemotherapy. This combination also has exciting potential as treatment for early stage breast cancer, a hypothesis that is being evaluated now in the global ALTTO trial." Dr. O'Shaughnessy serves as co-chair of the US Oncology Breast Cancer Research Committee and associate director for clinical research for US Oncology.

In addition to Dr. O'Shaughnessy's presentation, physicians affiliated with US Oncology participated in 23 oral and poster presentations and published studies at this year's ASCO conference. Findings were presented on a variety of disease states including breast, lung, genitourinary, gynecologic, and melanoma.

Breast

-- Nicholas Robert, M.D., Fairfax-Northern Virginia Hematology-Oncology,

co-chair US Oncology Breast Cancer Research Committee: Results of a

Phase II study of pemetrexed as first-line chemotherapy for advanced

or metastatic breast cancer

-- Michael Danso, M.D., Virginia Oncology Associates: Phase II trial of

weekly administration of nabpaclitaxel in combination with bevacizumab

in women with metastatic breast cancer (MBC)

-- Mary Ann Allison, M.D., Comprehensive Cancer Centers of Nevada-Siena

and Joanne Blum, M.D., Ph.D., Texas Oncology-Baylor Charles A Sammons

Cancer Center: Phase II study of eribulin mesylate in patients with

locally advanced or metastatic breast cancer (MBC) previously treated

with an anthracycline, taxane, and capecitabine

-- Sasha Vukelja, M.D., Texas Oncology-Tyler: Phase II and Phase III

study of the efficacy of nab-paclitaxel in patients with poor

prognostic factors or with anthracycline-resistant metastatic breast

cancer (MBC)

-- Frankie Holmes, M.D., Texas Oncology-Houston Memorial City,

US Oncology network associate chair Breast Cancer Research Committee,:

Phase II study on transcriptional profiles of triple receptor-negative

breast cancer: Are Caucasian, Hispanic and African-American different?

Lung

-- Charles Weissman, M.D., New York Oncology-Hematology--Latham: Phase

III open-label comparison of gemcitabine/oxaliplatin versus

paclitaxel/carboplatin as first-line therapy for advanced non-small

cell lung cancer (NSCLC)

Genitourinary

-- Guru Sonpavde, M.D., Texas Oncology-Deke Slayton Cancer Center: Phase

II study of Azacitidine for castration-resistant prostate cancer

progressing on combined androgen blockade

-- Phillip Periman, M.D., Texas Oncology-Amarillo: Phase II study of

Sunitinib malate for metastatic castration-resistant prostate cancer

following docetaxel-based chemotherapy

-- Allen Cohn, M.D., Rocky Mountain Cancer Centers-Midtown, co-chair,

US Oncology GI Cancer Research Committee: Phase III Panitumumab (pmab)

regimen evaluation in colorectal cancer to estimate primary response

to treatment (PRECEPT): effect of KRAS mutation status on second-line

treatment (tx) with pmab and FOLFIRI

-- Thomas Hutson, D.O., PharmD, Texas Oncology-Baylor Charles A Sammons

Cancer Center, associate chair, US Oncology GU Cancer Research

Committee,: RAD001 plus best supportive care (BSC) vs BSC plus

placebo in patients with metastatic renal cell carcinoma (RCC), which

has progressed on VEGF-TKI therapy: results from a randomized,

double-blind, multicenter Phase III study; Phase III randomized study

of overall survival with sunitinib versus interferon (IFN)-alfa as

first-line treatment of metastatic renal cell carcinoma (mRCC);

Multicenter, Phase I/II study of sunitinib in combination with

docetaxel and prednisone in patients with metastatic

castrate-resistant prostate cancer (mCRPC)-preliminary results;

Biomarker analysis and final results of a phase II renal cell

carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis

inhibitor; A multicenter, prospective Phase II trial of sorafenib in

patients (Pts) with metastatic clear cell renal cell carcinoma

(mccRCC) refractory to prior sunitinib or bevacizumab

-- Kelly Pendergrass, M.D., Kansas City Cancer Center-South:

Characterization of hyperglycemia, hypercholesterolemia, and

hyperlipidemia in patients with advanced renal cell carcinoma

treated with temsirolimus or interferon

Gynecologic

-- Michael Teneriello, M.D., Texas Oncology-Austin Central, co-chair,

US Oncology Gynecologic Cancer Research Committee: Phase III trial of

induction gemcitabine (G) or paclitaxel (T) plus carboplatin (C)

followed by elective T consolidation in advanced ovarian cancer (OC):

Interim analysis of induction chemotherapy

Melanoma

-- William Stephenson, M.D., Kansas City Cancer Center-South: PhaseI/II

study of imexon (AMP) plus dacarbazine (DTIC) in patients (Pts) with

metastatic malignant melanoma

Leukemia

-- Roger Lyons, M.D., Cancer Care Centers of South Texas-Medical Center:

Phase II study of single agent clofarabine in previously untreated

older adult patients with acute myelogenous leukemia (AML) unlikely to

benefit from standard induction chemotherapy

Solid Tumors

-- William Stephenson, M.D., Kansas City Cancer Center-South: Phase I

study multicenter study to assess the safety, tolerability, and

pharmacokinetics of AZD4877 administered twice weekly in adult

patients with advanced solid malignancies

-- Robert Raju, M.D., Dayton Oncology & Hematology-Kettering: An open

label Phase I dose escalation study of ADH-1 in combination with

chemotherapy in subjects with N-Cadherin expressing solid tumors

Lymphoma and Plasma Cell Disorders

-- Alan Feiner, M.D., Rocky Mountain Cancer Centers-Rose, and John

Mattern, D.O., Virginia Oncology Associates-Newport News: Primary

therapy of Waldenstrom's macroglobulinemia with bortezomib,

dexamethasone and rituximab: results of WMCTG Clinical Trial 05-180

About US Oncology Research

The US Oncology Research network is an established community-based research operation specializing in all phases of cancer clinical trials. The research network currently has 595 physicians actively enrolling patients, 109 research sites, and is currently involved in 63 open research trials. The network has contributed to the development of 24 of 30 of the latest cancer-fighting drugs approved by the Food and Drug Administration for use. Since 1993, more than 32,000 patients have participated in clinical trials managed by US Oncology network practices. For more information, visit the "Research" section under "Our Services" on the company's Web site, http://www.usoncology.com.

About US Oncology, Inc.

US Oncology, headquartered in Houston, works closely with physicians, manufacturers and payers to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology's expertise in supporting every aspect of the cancer care delivery system -- from drug development to treatment and outcomes measurement, enables the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,247 physicians operating in 472 locations, including 91 radiation oncology facilities in 39 states. For more information, visit the company's Web site, http://www.usoncology.com.


'/>"/>
SOURCE US Oncology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
3. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
4. BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Cell Therapeutics, Inc. (CTI) Announces Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting
8. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
9. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
10. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
11. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Medical, Inc. (Nasdaq: AEMD ), the pioneer ... diseases, today announced results for the third quarter ... --> --> "Beyond ... quarterly call, we strategically advanced pre-clinical and clinical ... the Aethlon Hemopurifier® as a leading broad-spectrum countermeasure ...
(Date:2/4/2016)... N.Y. , Feb. 4, 2016  AMRI (NASDAQ:  AMRI) ... President of Pfizer Inc. and President of Pfizer Global Supply, ... as of February 4, 2016. In addition, the Company announced ... of the audit committee since 2010, has retired from the ... and attention to his other business ventures.  ...
(Date:2/4/2016)... PUNE, India , February 4, 2016 ... to the new Market Research Report "North American Automated ... and Fully-Automated External Defibrillators), by End-User (Public Facilities, Hospitals, ... North American automated external defibrillators (AED) report defines and ... of the revenue. This market is estimated to grow ...
Breaking Medicine Technology:
(Date:2/6/2016)... ... February 06, 2016 , ... ... MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO ... in the world with an estimated 5000 perioperative nurses in attendance to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Steven Tonkinson, 36, of ... completed every year since it started in 2003. This year, he ran all 26.2 ... fellow runners and NBA team the Miami Heat. , This Sunday, while many are ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... After years as an active staff surgeon ... and cosmetic surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic ... first three-year term as chief and began a second three-year term in January of ...
(Date:2/5/2016)... York, New York (PRWEB) , ... February 05, 2016 , ... ... gym use and find themselves having to wait longer to access the treadmills. It’s ... their New Year’s resolutions to lose weight and get in shape by joining gyms, ...
Breaking Medicine News(10 mins):